Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer
Dec 11, 2017 21:05 pm UTC| Business
BURLINGTON, Mass., Dec. 11, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Scott Kelley, M.D., has been named Chief Medical Officer. Dr. Kelley previously served as the company’s Vice President of...
Dec 11, 2017 21:05 pm UTC| Business
-- Avid Bioservices Records Revenues of $12.8 Million in the Second Quarter of FY2018 -- -- Transition to a Dedicated CDMO Business Nearing Completion -- TUSTIN, Calif., Dec. 11, 2017 -- Peregrine...
Dec 11, 2017 21:05 pm UTC| Business
Nine of fourteen (64%) of patients treated for more than one month showed a 50% or greater improvement in total skin diseaseSeven patients have achieved at least a 50% improvement that has been durable for at least four...
Dec 11, 2017 21:05 pm UTC| Business
NEW YORK, Dec. 11, 2017 -- At the end of the settlement date of November 30, 2017, short interest in 2,348 Nasdaq Global MarketSM securities totaled 7,455,601,576 shares compared with 7,492,878,677 shares in 2,353...
Dynagas LNG Partners LP Announces Results of 2017 Annual General Meeting of Limited Partners
Dec 11, 2017 21:05 pm UTC| Business
MONACO, Dec. 11, 2017 -- Dynagas LNG Partners LP (the “Partnership”) (NYSE:DLNG) conducted its Annual General Meeting of Limited Partners on December 7, 2017 in Athens, Greece. The following resolutions were approved: ...
RCM Technologies, Inc. Declares Special Cash Dividend of $1.00 per Share
Dec 11, 2017 21:05 pm UTC| Business
PENNSAUKEN, N.J., Dec. 11, 2017 -- RCM Technologies, Inc. (Nasdaq:RCMT), a premier provider of business and technology solutions designed to enhance and maximize the operational performance of its customers through the...
Dec 11, 2017 21:05 pm UTC| Business
- Ivosidenib and Enasidenib Evaluated in Combination with Standard Induction (7+3) Chemotherapy or Azacitadine in Newly Diagnosed Patients From Two Phase 1 Studies - - Phase 3 Trial of Ivosidenib or Enasidenib Combined...